Increase In Treatment-Resistant Depression Driving The Growth Of The Market Due To Increasing Demand For Alternative Therapies: Pivotal Factor Influencing Esketamine Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Esketamine Market Size Growth Forecast: What to Expect by 2025?
Recently, the esketamine market has shown significant growth, and it is projected to expand from $1.37 billion in 2024 to $1.51 billion in 2025. This equates to a compound annual growth rate (CAGR) of 9.9%. The previous growth in this market is due to a variety of factors, including an increased patient base, a rising global prevalence of mental health disorders, enhanced disease state awareness, greater demand for innovative treatment alternatives, and positive regulatory approvals.

How Will the Esketamine Market Size Evolve and Grow by 2029?
There is a prediction of a swift expansion in the size of the esketamine market in the upcoming years. It is projected to escalate to "$2.26 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. The acceleration in the projected period is driven by the heightened occurrence of treatment-resistant depression, escalating investments in research and development initiatives, the requirement for intelligent healthcare infrastructure, the emerging pattern of telehealth services, and the acceptance of esketamine as a potent treatment method. Key trends in the forecast span are collaborations between biotechnology companies and mental health entities, employment of robotics in healthcare utilities, personalized treatment plans, sensor-enabled gadgets, and the potential for combined therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Drivers Are Propelling the Growth of Esketamine Market Forward?
The anticipated growth of the esketamine market is largely driven by the escalating incidence of treatment-resistant depression (TRD). TRD is characterized as depression that remains unimproved despite administering at least two distinct antidepressants at suitable doses and for an adequate duration. The phenomenon of TRD is on the rise due to the limited effectiveness of traditional antidepressants, often resulting in extended and recurring depressive episodes. Esketamine serves as an effective solution for TRD, owing to its quick-acting mechanism that focuses on NMDA receptors. This presents a beneficial alternative for patients who fail to respond to conventional antidepressants. A significant example of this escalating condition was reported in September 2023 by the National Institute of Mental Health (NIMH), a federal agency in the U.S. They noted that approximately 30% of U.S. individuals with major depressive disorder demonstrated resistance to standard treatments in that year. This increasing prevalence of TRD is therefore a key factor influencing the expansion of the esketamine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Emerging Trends Are Transforming the Esketamine Market in 2025?
Prominent companies within the esketamine market have been concentrating their efforts on the creation of state-of-the-art treatment techniques, such as monotherapy, that aim to exceed the comfort provided by placebo treatments. Monotherapy is a method that involves managing a disease or a health issue using only one form of medication or therapy, rather than a combination. For example, in January 2025, Johnson & Johnson, a pharmaceutical corporation based in the U.S., disclosed that the U.S. Food and Drug Administration (FDA) had given approval for SPRAVATO (esketamine) as the first solitary therapy for adults suffering from treatment-resistant depression (TRD). The endorsement, based on the support of clinical trials, affirmed that SPRAVATO can provide rapid relief from depressive symptoms, with noticeable progress seen within 24 hours. This innovative development provides a crucial alternative for the nearly 30% of people who fail to react to conventional antidepressants, thereby eliminating the need for simultaneous oral medication. Even though SPRAVATO holds a promising safety record, it's administered under a Risk Evaluation and Mitigation Strategy (REMS) to deal with possible side effects. This accomplishment signifies a substantial progression in TRD treatment, supplying new hope for improved patient prognosis.

What Are the Key Segments in the Esketamine Market?
The esketamine market covered in this report is segmented -

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types
2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders
3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients
4) By Application: General Anesthetic, Treatment-Resistant Depression
5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:
1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets
2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray
4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Who Are the Key Players Shaping the Esketamine Market's Competitive Landscape?
Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

What Geographic Markets Are Powering Growth in the Esketamine Market?
North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.